Physician profile
Brian C Ham
NPI 1053505909
$4,757.34
in general payments reported to CMS, 2019-2025
23 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,193 · 2022: $1,282 · 2023: $960 · 2024: $768 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $849.77 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $786.18 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $604.17 | 2021-2025 | Mounjaro, Emgality, Jardiance |
| Abbvie INC. | $527.18 | 2021-2025 | |
| Glaxosmithkline, LLC. | $377.13 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.78 | 2021-2022 | |
| Pfizer INC. | $175.21 | 2023-2025 | |
| Abbott Laboratories | $174.54 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.96 | 2021-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $119.96 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Phathom Pharmaceuticals, INC. | $105.57 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $99.02 | 2021-2023 | |
| Corcept Therapeutics | $97.41 | 2022-2023 | Korlym |
| Scilex Pharmaceuticals INC. | $77.84 | 2022-2023 | Ztlido |
| Kowa Pharmaceuticals America, INC. | $58.01 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $57.71 | 2021-2022 | |
| Exact Sciences Corporation | $56.62 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $31.24 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.85 | 2022 | |
| Scpharmaceuticals INC. | $19.32 | 2025 | |
| Almatica Pharma LLC | $17.22 | 2023 | Loreev Xr |
| Amgen INC. | $15.45 | 2024 | Otezla, Repatha |
| Horizon Therapeutics Plc | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Ham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.